C1QTNF6 is a Prognostic Biomarker and Related to Immune Infiltration and Drug Sensitivity: A Pan-Cancer Analysis.

The discovery of reliable cancer biomarkers could tune a diagnosis and improve the way patients are treated. However, many cancers lack robust biomarkers. has been preliminarily elucidated for its role in some tumors. However, no pan-cancer analysis has been performed to comprehensively explore the value of . Data from the TCGA database, GTEx database stored in the USUC Xena were used for analyzing the profiles of expression in normal and tumor tissues in pan-cancer. Subsequently, the gene alteration rates of were acquired on the online web cBioportal. With the aid of the TCGA data, the association between mRNA expression and copy number alterations (CNA) and methylation was determined. Survival analyses of were carried out. Moreover, the tumor biological and immunological characteristics of were clarified in the forms of the correlation between expression and hallmark Pathway scores in MsigDB database, immune cell infiltration, immune-related genes. We conducted a GSEA of to illustrate its potential biological functions. In addition, GDSC2 data with 198 drugs were adopted to explore drug sensitivity with the change of expression. was overexpressed in many types of cancer, Survival analysis showed that independently served as a prognostic indicator for poor survival in many tumors. Besides, we also identified a positive correlation between and cancer hallmark pathway score, tumor microenvironment related pathways score (TMEp score), and immune characteristic. In terms of drug sensitivity analysis, we found higher expression level of predicts a high IC50 value for most of 198 drugs which predicts drug resistance. Our study provides a new biological marker for pan-cancer, which is beneficial to the diagnosis and treatment of cancer, which bring a new therapeutic target for tumors.